Obalon Therapeutics To Present at Two Upcoming Investor Conferences

SAN DIEGO, Nov. 14, 2016 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer and Bill Plovanic, Chief Financial Officer of Obalon will present at two upcoming investor conferences:

  • Stifel 2016 Healthcare Conference
    Wednesday, November 16, 2016 at 8:00 a.m. Eastern Time
    Lotte New York Palace Hotel, New York, NY
    Webcast Available at: http://wsw.com/webcast/stifel5/obln

  • Canaccord Genuity Medical Technologies & Diagnostics Forum
    Thursday, November 17, 2016 at 4:00 p.m. Eastern Time
    Westin Grand Central, New York, NY
    Webcast Available at: http://wsw.com/webcast/canaccord24/obln

Live audio webcasts of the presentations can be accessed at the links above. Replays of the webcasts will be available for 90 days following each presentation.Roblox HackBigo Live Beans HackYUGIOH DUEL LINKS HACKPokemon Duel HackRoblox HackPixel Gun 3d HackGrowtopia HackClash Royale Hackmy cafe recipes stories hackMobile Legends HackMobile Strike Hack

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN), is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling.